> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biogen Awarded Priority Review Voucher
- URL: https://www.fdaweb.com/biogen-awarded-priority-review-voucher/
- Published: 2017-03-06T12:00:00.000Z
- Updated: 2026-09-14T22:09:57.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138129

*Federal Register* Notice: FDA has awarded Biogen a priority review voucher (PRV) for gaining approval of rare disease drug Spinraza (nusinersen), indicated for treating spinal muscular atrophy in pediatric and adult patients. The PRV was awarded under a provision that encourages development of new drugs and biologics for rare pediatric diseases. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-03-06/pdf/2017-04228.pdf?ref=fdaweb.com).